• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Glucose management company LifeScan emerges from Ch. 11

December 9, 2025 By Sean Whooley

LifeScan OneTouch appLifeScan announced today that it emerged from its Chapter 11 financial restructuring process as it looks to continue advancing its glucose management offerings.

Malvern, Pennsylvania-based LifeScan said in July that it entered into a restructuring support agreement. To implement it, the company filed for Chapter 11. In October, the Chapter 11 bankruptcy reorganization plan received U.S. Bankruptcy Court approval.

Through the process, Lifescan said it eliminated more than 75% of its debt. This gives it the financial flexibility to move forward with its glucose management technology.

In connection with the emergence, LifeScan is now owned by a group of its existing lenders. That includes Canyon Parnters and Brigade Capital Management. The company expects to move forward serving more than 20 million people with its OneTouch brand backed by a stronger balance sheet and committed new ownership group.

The company develops the OneTouch Bluetooth-connected blood glucose meter and mobile diabetes app. It aims to provide simplicity, accuracy and trust in diabetes management.

“Today signals a powerful new beginning for LifeScan and enables us to lead from a position of strength,” said Valerie Asbury, CEO. “We are reinforcing our commitment to the patients who rely on our products now that we have the flexibility to invest where it matters most: improving affordability and accessibility in key countries and markets. I’m grateful to our employees and partners whose dedication to LifeScan made this possible.”

Filed Under: Business/Financial News, Diabetes, Featured, Patient Monitoring, Technology, Wall Street Beat Tagged With: lifescan

IN CASE YOU MISSED IT

  • Abbott partners with Berry Street to add nutrition coaching to Lingo
  • Dexcom CFO to expand into COO role
  • Beta Bionics insulin patch pump scores FDA clearance
  • Medtronic moves to divest final stake in MiniMed
  • Dexcom adds former Stryker CFO to board

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS